Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Söling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K. Dechow T, et al. Among authors: potthoff k. Eur J Haematol. 2022 Feb;108(2):133-144. doi: 10.1111/ejh.13719. Epub 2021 Nov 15. Eur J Haematol. 2022. PMID: 34714555 Free PMC article.
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J, Zaiss M, Losem C, Schmitz S, Niemeier B, Harde J, Hannig CV, Harich HD, Müller J, Klausmann M, Tessen HW, Potthoff K. Wehmeyer J, et al. Among authors: potthoff k. Eur J Haematol. 2018 Dec;101(6):766-773. doi: 10.1111/ejh.13160. Epub 2018 Oct 25. Eur J Haematol. 2018. PMID: 30091166
Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Marschner N, Salat C, Söling U, Hansen R, Grebhardt S, Harde J, Nusch A, Potthoff K. Marschner N, et al. Among authors: potthoff k. Clin Breast Cancer. 2018 Dec;18(6):e1323-e1337. doi: 10.1016/j.clbc.2018.07.010. Epub 2018 Aug 10. Clin Breast Cancer. 2018. PMID: 30100104 Free article.
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
Fietz T, Lück A, Schulz H, Harde J, Losem C, Grebhardt S, Wolff T, Potthoff K, Müller U, Zaiss M, Kurbacher CM. Fietz T, et al. Among authors: potthoff k. Curr Med Res Opin. 2019 Jul;35(7):1127-1138. doi: 10.1080/03007995.2018.1560200. Epub 2019 Jan 21. Curr Med Res Opin. 2019. PMID: 30557099
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schröder H, Jaehnig P, Potthoff K, Lerchenmüller C. Decker T, et al. Among authors: potthoff k. Breast Cancer Res Treat. 2019 Aug;176(3):637-647. doi: 10.1007/s10549-019-05280-2. Epub 2019 May 21. Breast Cancer Res Treat. 2019. PMID: 31115844 Clinical Trial.
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K. Decker T, et al. Among authors: potthoff k. BMC Cancer. 2020 Apr 6;20(1):286. doi: 10.1186/s12885-020-06747-y. BMC Cancer. 2020. PMID: 32252684 Free PMC article. Clinical Trial.
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Welt A, Wiesweg M, Theurer S, Abenhardt W, Groschek M, Müller L, Schröder J, Tewes M, Chiabudini M, Potthoff K, Bankfalvi A, Marschner N, Schuler M, Breitenbücher F. Welt A, et al. Among authors: potthoff k. Cancer Med. 2020 Jul;9(13):4527-4539. doi: 10.1002/cam4.3092. Epub 2020 Apr 30. Cancer Med. 2020. PMID: 32352244 Free PMC article. Clinical Trial.
59 results